Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Biotech
Galectin's stock halves after phase 3 MASH trial misses goal
Since the biotech shared the phase 3 data this morning, the company’s stock has dropped 54%, from $2 per share to 92 cents.
Gabrielle Masson
Dec 20, 2024 2:40pm
Applied CEO steps down in wake of FDA rejection, warning letter
Dec 20, 2024 12:51pm
Sponsored
Hybrid FSP/FSO Solutions Keep Biotech Trials on Time and on Budget
Nov 1, 2024 8:00am
Sanofi scoops up China rights to Cytokinetics’ heart disease med
Dec 20, 2024 11:07am
Sponsored
Carl Sailer on AI, market trends, and strategic planning in biotech
Oct 28, 2024 8:00pm
Apollomics, after giving up on leukemia drug, posts ph. 3 fail
Dec 20, 2024 9:30am